Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an update.
RemeGen Co., Ltd. has initiated the election process for its third board session as the term of the current board nears expiry, in line with PRC company law, applicable listing rules and its articles of association. Until new directors are approved at the upcoming annual general meeting, existing board members will continue performing their duties to ensure continuity of corporate governance.
The company has nominated four executive and one non-executive director candidates, mostly existing board members, alongside three independent non-executive director candidates, one of whom is new and all of whom have affirmed their independence under Hong Kong listing rules. Two current directors, an executive and a non-executive, will retire at the end of the second board term, with one remaining as vice president and the other leaving all roles, marking a managed transition in leadership that maintains board diversity and regulatory compliance.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong. The group focuses on developing and commercializing innovative therapies, operating under PRC company law and Hong Kong listing rules, with a governance structure that includes executive, non-executive and independent non-executive directors.
Average Trading Volume: 4,207,660
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.14B
Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.